Several species of Plasmodium cause a broad spectrum of human disease that range from nausea and fever to severe anemia, cerebral malaria, and multiorgan failure. In malaria-endemic countries, continuous exposure to Plasmodium sporozoite inoculations and subsequent blood infections elicit only partial and short-lived immunity, which gradually develops over many years of parasite exposure and multiple clinical episodes. The ambitious goal of malaria vaccinology over the past 70 years has been to develop an immunization strategy that mounts protection superior to naturally acquired immunity. Herein, three principal concepts in evidence-based malaria vaccine development are compared. Feasible leads are typically stand-alone subunit vaccine approaches that block Plasmodium parasite life cycle progression or parasite/host interactions, and they constitute the majority of candidates in preclinical research and early clinical testing. Integrated approaches incorporate malaria antigen(s) into licensed or emerging pediatric vaccine formulations. This strategy can complement the malaria control portfolio even if the antimalarial component is only partially effective and has led to the development of the only candidate vaccine to date, namely RTS,S-AS01. Experimental whole parasite vaccine approaches have been repeatedly shown to elicit sterile and lasting protection against identical parasite strains, but mass production, proof of broad protection against different parasite strains, and routes of vaccine delivery remain significant translational road blocks. Global access to an effective and affordable malaria vaccine will critically depend on innovative translational research that builds on a better molecular understanding of Plasmodium biology and host immunity.
Introduction
Malaria remains the most important mosquito-borne infectious disease and is caused by blood infection with Plasmodium parasites [1] . These obligate intracellular pathogens belong to the phylum Apicomplexa, which are single-cell eukaryotes that coevolved with their respective hosts across the entire animal kingdom [2] . What distinguishes Plasmodium is their unidirectional population expansion first in the liver and then in red blood cells before differentiation into sexual stages that colonize Anopheles mosquitoes [3] .
Plasmodium stage conversion over the course of the human infection offers multiple targets for vaccineinduced immunity (Fig. 1 ), but the parasite is tailored to reinfect the host lifelong. Naturally acquired immunity develops only gradually after > 20 clinical episodes over the course of many years [4] , but it is never sterile [5] . Natural immunity mostly comprises plasma B cells that produce antibodies against variant parasite-encoded erythrocyte surface antigens, such as Plasmodium falciparum erythrocyte membrane proteins (PfEMP1s) and, to a lesser extent, merozoite proteins ( Fig. 1) [5] . In marked contrast, acute infections by viral and some bacterial pathogens elicit lasting and frequently lifelong protection against reinfection, often after a single infection. This immunological memory is the basis for protective vaccines [6] and clearly missing in malaria and other chronic infectious diseases, such as tuberculosis. Accordingly, simply extrapolating successful antimicrobial vaccines to malaria is likely inadequate, and despite intense efforts in malaria vaccinology over the past 70 years the goal to develop an effective malaria vaccine that performs superior to naturally acquired immunity has not yet been achieved.
A hypothetical malaria vaccine is highly unlikely to replace existing malaria control tools, unless it achieves complete sterilizing immunity. Rather a vaccine will be an integral part of malaria control programs, which include access to rapid diagnosis and treatment with Artemisinin-based combination therapies, ownership of long-lasting insecticide treated nets, and regular campaigns of indoor residual spraying with a suitable insecticide. Malaria control has been successful over the past 10 years because of exceptional donor commitment. Continuation of effective malaria management and further reduction in the malaria disease burden in high-risk endemic areas critically depends on sustained recognition of malaria as a global health priority. Furthermore, widespread tolerance against insecticides in Anopheles vector populations and parasite resistance against every approved antimalarial drug on the market emphasize the urgent need for a safe and effective vaccine. Sporozoites are the infectious agents that are injected during the probing phase of an infectious Anopheles bite (Fig. 1) . They actively migrate through the skin in search of a blood capillary to be flushed to the final target organ, the liver [3, 17] . Antibodymediated inhibition of sporozoite infection of the liver can reduce the initial parasite inoculum and requires the induction of long-lived antibody responses [18] . Accordingly, antisporozoite vaccines should stimulate the formation of germinal center B cells, which can maintain an effector phenotype and initiate rapid plasma cell differentiation through interaction with memory T follicular helper cells [19] . However, also in the secondary response, upon parasite antigen rechallenge, high levels of inhibitory antibodies are only formed within a few days. In the meantime, the sporozoite is already in full liver stage development. Accordingly, antisporozoite vaccine strategies that elicit antibodies can only achieve substantial reduction in Plasmodium transmission in subsequent infections and have an impact over time. However, they consistently fail in preventing malaria infections [20] and, hence, are not considered in travel medicine.
During the obligate pre-erythrocytic phase in the liver, Plasmodium undergoes an enormous population expansion resulting in the formation of thousands of first-generation merozoites (Fig. 1) . Only during liver stage maturation is the parasite susceptible to direct Tcell-mediated killing, and this period is long enough (~7 days) for secondary recall responses [3, 21] . Lasting and robust antiliver stage immunity is the principal mechanism for the experimental success of vaccine strategies that lead to live, but developmentally arrested, liver stages [22] [23] [24] [25] . Although work in murine malaria models has consistently recovered antigen-specific cytolytic effector memory CD8 + T cells as the main cell type that recognizes and lyses infected hepatocytes [26-29], a similar important role remains to be shown for human malaria.
Merozoites are tailor-made to actively and rapidly invade red blood cells (Fig. 1 ). This second asexual replication phase inside erythrocytes is the exclusive cause of malaria and an ideal target to reduce the incidence of clinical attacks. However, antibody-mediated inhibition and destruction of merozoites [30] is limited to a very brief (~30 s) moment, when the parasite is outside its host cell and in the process of invading a new erythrocyte. Many candidate antigens that perform vital functions in the invasion process are stored in specialized organelles, termed micronemes, rhoptries, and dense granules, and are sequentially released upon intimate merozoite contact with the erythrocyte surface, thus further limiting exposure to inhibitory antibodies [31] . A population-based study of antibody responses in malaria-endemic countries did not return any signatures of protection, and many candidate antigens were recognized to a similar extent by protected and susceptible individuals [32] . In addition, increasing evidence suggests that memory B cells, which are the principal antibody-secreting cells that target blood stage antigens upon vaccine-induced immunity, appear to contract remarkably early [33] .
Severe malaria in a proportion of children infected with P. falciparum remains a leading cause of death in Afrotropical regions [34] . After invasion, P. falciparum extensively refurbishes the host erythrocyte and exports PfEMP1s and other variant antigens to the surface. Binding of infected erythrocytes to cognate receptors on the vascular endothelium, a process termed cytoadhesion, is crucial to avoid splenic clearance and results in a large pathological spectrum, ranging from capillary occlusion and hypoxia to tissue inflammation and multiorgan failure [35] . A broad range of memory B cells that target the P. falciparum-encoded surface protein repertoire is gradually acquired during infancy and childhood and reflects the slow acquisition of antidisease immunity in malaria-endemic areas. Whether other human Plasmodium species, including Plasmodium vivax, express parasite-encoded surface markers that can be targeted by inhibitory antibodies remains an unsolved matter.
A proportion of merozoites eventually differentiate into sexual stages, which can recombine and complete the life cycle upon ingestion by an Anopheles mosquito. Although of no immediate benefit to the vaccinated individual high-titer antibodies against gametocytes and the diploid zygote might aid in reduction of Plasmodium transmission on a community-level [36] . However, when prioritizing a small subset of candidate antigens for the most vulnerable population, infants and pregnant women, gamete and ookinete surface proteins are negligible.
Together, two of the five parasite stages in the mammalian host, namely liver stages and parasite antigens on the infected erythrocyte surface, represent promising targets for vaccine strategies. Liver stages can be targeted in all Plasmodium species and an effective vaccine can elicit complete protection against blood infection. But how to accurately induce a range of effector memory CD8 + T cells that home to the liver upon reinfection remains a principal problem in vaccinology [37] . Antibody-mediated inhibition of P. falciparumencoded erythrocyte surface proteins can prevent disease and targets the long replication phase inside red blood cells. But management of antigenic variation is a persistent challenge. On the other hand, induction of antibody-mediated inhibition of sporozoite and merozoite invasion or gamete fusion in the mosquito midgut is less demanding. While either one may offer synergistic benefits to an antiliver stage or anticytoadhesion vaccine, none are likely to curtail Plasmodium life cycle progression on their own. It follows that malaria vaccine research aims at developing a multicomponent, multistage vaccine, similar to pediatric combination vaccines against multiple childhood diseases.
Feasible leads: testing one antigen at a time Until date, the vast majority of candidate antigens are designed as stand-alone malaria subunit vaccines (Table 1) . Major advantages of a distinct antigen formulation include the potential feasibility to produce a defined malaria vaccine under good manufacturing procedures, at reasonable cost, and in a formulation that is thermostable and easy to deliver intramuscularly to human subjects. Accordingly, identification of a protective antigen and its translation to a safe and protective malaria subunit vaccine would be the most desirable solution. Over the past 30 years, a large range of candidate antigen formulations often included parasite antigens in the historic order of recombinant cloning. They encompassed initially the major sporozoite surface proteins (SSPs) circumsporozoite protein (CSP/SSP1) and thrombospondin-related anonymous protein (TRAP/SSP2), the major merozoite surface proteins 1-3 (MSP1-3), and the sexual stage antigens 25 and 230 (s25, s230). However, experimental proof that any of the Plasmodium antigens is a signature of protective immunity as opposed to parasite exposure remains elusive [32] .
A landmark study established that a recombinant malaria vaccine, comprising MSP1, MSP2, and ringinfected erythrocyte surface antigen, could exert selective pressure on parasite populations [38] . Although this finding signifies selective immunity against some antigens, in this case MSP2, it highlights swift parasite evasion of vaccine-induced selection pressure. A recent completion of the largest field trial of a blood stage vaccine candidate formulation, consisting of recombinant MSP3 and glutamate-rich protein (GLURP) in alum, in 1,735 children revealed no efficacy [39] , reiterating enormous challenges for merozoite vaccine approaches. These examples illustrate that antigenic variation and polymorphic antigens inevitably remain the largest obstacles for subunit vaccine development. Only informed design of a multivalent vaccine incorporating several invariant antigens can surmount this persisting challenge.
An alternative approach is the delivery of recombinant virus particles to express Plasmodium antigens, in this case TRAP/SSP2 [40] . Multiple rounds of optimization returned a heterologous prime/boost protocol with chimpanzee adenovirus 63 (ChAd63) and modified vaccinia Ankara virus (MVA), respectively. A recent small phase II study with 115 participants in Senegal showed no efficacy of this vaccine, and combined analysis with earlier data from Kenia returned only a small, albeit significant, delay until patency [40] .
A number of candidate antigens are still in the exploratory, preclinical phase or phase I safety testing. One example is a formulation with the cell-traversal protein for ookinetes and sporozoites (CelTOS), which was tested in an elegant murine infection model using transgenic chimeric parasites that express the P. falciparum protein [41] . Efficacy was very modest leading only to a twofold reduction in parasite liver load, which does not translate in any detectable effect on blood infection. Therefore, such a vaccine needs to be considerably re-engineered before any further testing, including in clinical trials. An attractive candidate is the VAR2CSA surface protein on infected erythrocytes, which mediates binding to chondroitin sulfate A (CSA) on the placenta and is a major factor for placental malaria in pregnant women [42] . Many obstacles remain, but the development of a tailored vaccine for young women will be an important stepping-stone toward anticytoadhesion vaccines. Finally, sexual stage antigens to induce transmission-blocking immunity can be tested in membrane feeding assays that partly mimic natural transmission to Anopheline mosquitoes. A systematic analysis returned two antigens, s25 and s230, as lead candidates for further investigation [43] . Together, feasible subunit vaccine approaches often deliver disappointing results in efficacy testing in the field, and conserved, nonredundant antigens that are indispensable for parasite life cycle progression need to be targeted to avoid counterselection [38] .
Integrated vaccines: taking advantage of existing pediatric vaccines
As a valuable addition to sustain affordable malaria control, a candidate vaccine needs to perform safely, and ideally efficiently, during neonatal and early life vaccination in resource-poor settings. Accordingly, such a malaria childhood vaccine needs to be tailored for integration into the expanded program of immunization. A powerful answer is to swing aboard licensed pediatric vaccines and add-on a malaria antigen. When combined as prime-boost strategy employing various vaccine approaches Plasmodium infections may be targeted in addition to the original pathogen (Table 2 ). Most importantly, because they are not stand-alone formulations integrated malaria vaccines are not required to perform to perfection from the beginning and can be improved iteratively, while always maintaining their original purpose, for instance complete protection against hepatitis B. It is, therefore, no surprise that only one candidate malaria vaccine, which followed this approach from the original design, ever advanced to pivotal phase III clinical trials, namely RTS,S/AS01 [44] . This vaccine formulation resembles an advanced hepatitis B vaccine, which was the world's first recombinant vaccine [45] . The vaccine consists of virus-like particles that can be produced in large fermenters by recombinant expression of the hepatitis B surface (S) antigen in Saccharomyces cerevisiae. The modified version still contains the S antigen as the largest protein portion, but in addition a smaller fraction consisting of a portion of the P. falciparum CSP, including the repeat region (R) and a T-cell epitope (T), fused to the S antigen. After multiple rounds of safety, immunogenicity and efficacy testing and improvements of a formulation with a potent liposome-based adjuvant, termed AS01 [46] , was selected for large-scale studies in at-risk populations [47] . In all studies, there was an initial short phase of protection against clinical malaria, in good correlation with exceptionally high antibody titers resulting from the vaccination scheme. As expected [20] , protection disappeared with the concurrent decrease in antibody titers after few months. Since initial protection was offset in later years the overall result was no efficacy [48] . These disappointing results reflect the fundamental differences in infection biology between viral and parasitic pathogens and cast doubt whether integrated approaches work in principle.
Nevertheless, the importance of the RTS,S/AS01 trials cannot be overestimated. They achieved the first advancement of a candidate vaccine against any of the three most important infectious diseases, HIV/AIDS, tuberculosis, and malaria, to phase III clinical trials, the set-up of clinical trials capacity in malaria-endemic countries, and a robust foundation for further developments. Important research topics are to uncover whether (a) CD4 + and CD8 + T-cell responses were induced in addition to antibody responses, (b) the selected Plasmodium antigen is central to pre-erythrocytic immunity, (c) alternative liver stage antigens might perform superior, and (d) biomarkers other than antibody titers might be better predictors of vaccine efficacy.
It will also be interesting to explore whether combination with other integrated formulations can improve the outcome (Table 2) . A recombinant yellow fever vaccine has been designed for preclinical studies in the murine malaria model Plasmodium yoelii [49] , a perhaps critical intermediate step toward translation, BCG Glaxo BCG-CS PfCSP full length [50] Pf, Plasmodium falciparum; Py, Plasmodium yoelii.
which was omitted entirely in the development of RTS,S/AS01 [10]. The yellow fever vaccine is based on a live, attenuated virus and a single dose protects for life. It will be interesting to explore potential protection against malaria once a suitable P. falciparum antigen is selected. The recombinant expression of P. falciparum CSP in the childhood tuberculosis vaccine strain Bacillus Calmette-Gu erin (BCG) is an interesting research direction, since this approach builds on the robust safety and efficacy of the only live, attenuated antibacterial pediatric vaccine [50] . Immunity against the complex intracellular bacterium Mycobacterium tuberculosis is likely to resemble anti-Plasmodium immunity much closer than antiviral immunity and also requires only one immunization dose. However, experimental testing of vaccine safety and efficacy proves difficult, since a preclinical animal model was not considered [50] . Other pediatric vaccines that are routinely delivered, including against measles, might also serve as suitable platforms for integrated malaria vaccine strategies.
Attenuated liver stages: benchmark experimental malaria vaccines
In recognition of the complex molecular make-up and intriguing escape mechanisms of Plasmodium parasites as well as the persistent challenges to subunit malaria vaccines, major efforts now return to the origins of malaria vaccine development [22] . The unifying principle is to elicit lasting, sterile immunity by immunization with live Plasmodium sporozoites, which cannot progress to blood infection (Table 3 ).
Early proof of principle studies demonstrated sterile immunity in humans that were immunized by exposure to c-irradiated P. falciparum-infected mosquitoes, and these findings could be consistently repeated [51] . Mosquito delivery of c-irradiated sporozoites (cspz) was soon recognized unrealistic, but these studies were an impressive testimonial for the validity of the original concept [22] , the important contribution of murine malaria models for evidence-based malaria vaccine development [10] , and, perhaps most critical, the feasibility to develop a malaria vaccine on the basis of arrested liver stage development.
Limitations of the cspz production include strict dependence on biosafety level 3 facilities and batch-tobatch variations, because c irradiation induces uncontrolled DNA double-strand breaks. Moreover, the full range of liver stage-induced immunity may be missed, because cspz arrest very early in liver infection, immediately after sporozoite transformation [21] . A strong advantage of the cspz technology is the universal coverage of every human Plasmodium species and the ability to implement multiple vaccine strains, which can cover regional parasite diversity in the tropics [52] .
Some of the restrictions of cspz were overcome by targeted removal of stage-specific Plasmodium genes that perform vital functions for liver stage maturation [24] . Genetically arrested parasites (GAPs) can now be engineered as precision malaria vaccines, tailored to arrest at any given point in pre-erythroyctic development and harboring additional components, such as blood stage antigens and ligands to stimulate antigen presentation. Of note, occupational exposure or accidental mosquito release no longer pose health risks, greatly facilitating potential production in malariaendemic countries. P. falciparum GAPs have already advanced to clinical testing, and first safety and immunogenicity data are encouraging [53] . However, in marked contrast to cspz, GAP technology requires re-engineering by reverse genetics for every Plasmodium species and strain.
An alternative approach to stop blood infection is sporozoite delivery under simultaneous drug cover [21, 23, 25] . Again, the success of a preclinical model, where mice were given normal sporozoites together with the antimalarial drug chloroquine and enjoyed lasting protection against challenge infection [23], were repeated successfully in small human trials [54] . Drug cover can also be done with the antibiotic azithromycin, which leads to release of attenuated liver stage merozoites and superior protection [25] , and the 8-aminoquinoline primaquine, which eliminates developing and quiescent liver stages [55] (Table 3) . Major safety concerns with all drug cover approaches are patient To overcome all four roadblocks and reroute the development of whole sporozoite vaccines from a deadlock to a convincing road map, extensive bioengineering and basic science investments have to be made. But the complex infection biology of Plasmodium parasites might require complex solutions, such as whole parasite vaccines.
Conclusion and outlook
In the past malaria vaccinology has focused on concepts that were developed against acute infections with viral and bacterial pathogens. Eliciting strong recall antibody responses alone appear insufficient against Plasmodium parasites. These eukaryotic cells evolved sophisticated strategies to escape invasion inhibition by sequential secretion of redundant parasite ligands and to overcome recognition of visible antigens by antigenic diversity. Integration of candidate Plasmodium antigens into licensed vaccines for neonatal and childhood immunization remains largely underexplored. The historic momentum gained by multicenter clinical trials of RTS,S/AS01 should be utilized to advance this vaccine further and initiate immunological studies in murine malaria models to gain mechanistic insights into the potential effects against invading sporozoites and developing liver stages, which remain inaccessible in human subjects. Since the choice of target antigen is essential a better molecular understanding of what distinguishes a protective immune response from immune recognition of parasite exposure is important. For any subunit vaccine approach the necessary evidence to advance to clinical testing should be based on robust indications for signatures of protection. Whole sporozoite vaccines need to be 100% effective to be successful, but can also provide the missing roadmap and assist in prioritizing Plasmodium pre-erythrocytic antigens. Pioneering work beyond classical vaccine development, readiness of each stakeholder to start all over again, and public awareness of one of the most important challenges in medicine are vital to further accelerate malaria vaccinology. Yet, the discovery, development, and licensing of a malaria vaccine formulation, which meets all necessary requirements, including safety, affordability, accessibility, applicability, and efficacy, is far beyond the horizon.
